iPSC-derived allogenic cell therapy (PlateletBio)

N/A

Report date: 2025/03/20 16:04:42

Base Information

Drug NameiPSC-derived allogenic cell therapy (PlateletBio)
Drug Alias Nameplatelet-like cells (PlateletBio)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPurpura, Thrombocytopenic, Idiopathic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPlatelet BioGenesis Inc
China Registration ClassN/A

Develop Information

Active CompaniesPlatelet BioGenesis Inc
Inactive CompaniesN/A
Active IndicationsPurpura, Thrombocytopenic, Idiopathic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A